Drug firm Lupin today said it has launched its antibiotic Tobramycin inhalation solution in the US market.
The company has launched the product as it has received an approval from the US Food and Drug Administration (USFDA) earlier, Lupin said in a filing to BSE.
The company's Tobramycin Inhalation Solution USP, 300 mg/5 ml, is the generic version of Novartis Pharmaceuticals Corporation's Tobi 300 mg/5 ml, it added.
The product is indicated for the management of cystic fibrosis patients with P aeruginosa, Lupin said.
As per IQVIA MAT April 2018 data, Tobramycin inhalation solution USP, 300 mg/5 ml, had annual sales of nearly USD 99 million in the American market, it added.
Shares of Lupin today closed at Rs 869.60 per scrip on BSE, up 1.79 per cent from its previous close.
Disclaimer: No Business Standard Journalist was involved in creation of this content